HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 231 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,115 | +237.9% | 29,191 | +219.0% | 0.11% | +164.3% |
| Q2 2023 | $330 | -61.7% | 9,152 | -59.4% | 0.04% | -46.8% |
| Q1 2023 | $861 | -99.9% | 22,543 | +7.7% | 0.08% | -24.0% |
| Q2 2022 | $921,000 | +205.0% | 20,930 | +22.9% | 0.10% | +116.7% |
| Q4 2019 | $302,000 | +48.0% | 17,036 | +43.5% | 0.05% | +41.2% |
| Q2 2019 | $204,000 | +3.6% | 11,871 | +9.9% | 0.03% | +25.9% |
| Q3 2018 | $197,000 | -17.9% | 10,806 | -24.1% | 0.03% | -25.0% |
| Q2 2018 | $240,000 | -76.0% | 14,235 | -72.1% | 0.04% | -75.8% |
| Q1 2018 | $1,000,000 | +440.5% | 51,050 | +380.0% | 0.15% | +396.7% |
| Q3 2017 | $185,000 | +8.2% | 10,636 | -20.2% | 0.03% | -6.2% |
| Q2 2017 | $171,000 | -11.4% | 13,336 | -31.9% | 0.03% | -38.5% |
| Q4 2016 | $193,000 | +43.0% | 19,589 | +75.0% | 0.05% | +44.4% |
| Q3 2016 | $135,000 | -4.3% | 11,193 | +5.7% | 0.04% | -25.0% |
| Q3 2015 | $141,000 | – | 10,594 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |